Pfizer buys King to beef up portfolio

first_img More From Our Partners Police Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgWhy people are finding dryer sheets in their mailboxesnypost.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.org980-foot skyscraper sways in China, prompting panic and evacuationsnypost.comRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comI blew off Adam Sandler 22 years ago — and it’s my biggest regretnypost.comUK teen died on school trip after teachers allegedly refused her pleasnypost.comBiden received funds from top Russia lobbyist before Nord Stream 2 giveawaynypost.comFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comKamala Harris keeps list of reporters who don’t ‘understand’ her: reportnypost.comKiller drone ‘hunted down a human target’ without being told tonypost.comSupermodel Anne Vyalitsyna claims income drop, pushes for child supportnypost.comMark Eaton, former NBA All-Star, dead at‘Neighbor from hell’ faces new charges after scaring off home Tuesday 12 October 2010 9:09 pm whatsapp Pfizer buys King to beef up portfolio Share PFIZER is to buy drug manufacturer King Pharmaceuticals for $3.6bn (£2.26m) to strengthen its portfolio before key patents on drugs such as its flagship cholesterol-reducer Lipitor expire next year.The world’s biggest pharmaceutical company will pay $14.25 (£8.95) per share for King from existing cash, a 40 per cent premium on King’s closing share price on Monday.Pfizer expects the deal to add about two cents to adjusted earnings per share in 2011 and 2012 and about three to four cents from 2013 to 2015. It has also reaffirmed its earnings forecast for 2012, when patents will have expired.Analysts said Pfizer is paying a relatively high premium but cost savings from absorbing King may be higher than announced. Pfizer expects to make savings of over $200m, half of which should be realised in the first year, but some believe it could be as high as $500m.The deal follows last year’s $67bn acquisition of Wyeth and is a move to address the huge anticipated revenue loss as Lipitor, the world’s biggest-selling prescription drug, starts to compete with generic alternatives from June 2011. Lipitor is expected to generate over $11bn revenues this year.The acquisition will give Pfizer a bigger share in the large and growing prescription pain relief market, where King is a leader. King recently launched Embeda, the first approved opiate-based pain reliever resistant to narcotic abuse, but generic competition to its drugs has hit profits.FAST FACTS | PfizerDeal brings bigger market share in pain relief. Pfizer expects to make $200m cost savings realised over three years.King Pharmaceuticals made $150.6m pre-tax profits on $1.8bn sales last year. Show Comments ▼ KCS-content Tags: NULL whatsapp by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryNoteabley25 Funny Notes Written By StrangersNoteableyTotal PastThe Ingenious Reason There Are No Mosquitoes At Disney WorldTotal PastMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailSerendipity TimesInside Coco Chanel’s Eerily Abandoned Mansion Frozen In TimeSerendipity TimesBrake For ItThe Most Worthless Cars Ever MadeBrake For ItBetterBe20 Stunning Female AthletesBetterBemoneycougar.comThis Proves The Osmonds Weren’t So Innocentmoneycougar.comHistorical GeniusHe Was The Smartest Man Who Ever Lived – But He Led A Miserable LifeHistorical Geniuslast_img

Leave a Reply

Your email address will not be published. Required fields are marked *